Anorexic effect of (R)-sibutramine: Comparison with (R)-sibutramine and (S)-sibutramine

Indian Journal of Physiology and Pharmacology

Volumn 51, Issue 2, 2007, Pages 175-178

  Bodhankar, Subhash L ^a   Thakurdesai, Prasad A ^a   Singhal, Shrawan ^a   Gaur, Vaibhav ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Anorexia; Motor activity; Sibutramine; Stereoisomerism

Indexed keywords

DRUG METABOLITE; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG MECHANISM; ENANTIOMER; FEMALE; FLUID INTAKE; FOOD INTAKE; LOCOMOTION; MALE; NONHUMAN; RAT; SCORING SYSTEM;

ADMINISTRATION, ORAL; ANIMALS; ANOREXIA; BODY WEIGHT; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FEMALE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; STEREOISOMERISM;

EID: 34547872826     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Klein S. Long-term pharmacotherapy for obesity. Obes Res 2004; 12 Suppl: 163S-166S.
2. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006; 29(1): 49-60.
3. Hansen DL, Toubro S,1 Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999; 23(10): 1016-1024.
4. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997; 21 Suppl 1: 825-829.
5. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26 (14): 1027-1048.
6. Link M, Novotna R, Suchanova B et al. The stereoselective biotransformation of the anti-obesity drug sibutramine in rat liver microsomes and in primary cultures of rat hepatocytes. J Pharm Pharmacol 2005; 57(3): 405-410.
7. Click SD, Haskew RE, Maisonneuve IM, Carlson JN, Jerussi TP. Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol 2000; 397(1): 93-102.
8. Fukagawa K, Sakata T. Monoaminergic anorectic agents. Nippon Yakurigaku Zasshi 2001; 118(5): 303-308.
9. Wortley KE, Heal DJ, Stanford SC. Modulation of sibutramine-induced increases in extracellular noradrenaline concentration in rat frontal cortex and hypothalamus by alpha2-adrenoceptors. Br J Pharmacol 1999; 128(3): 659-666.
10. Luque CA, Rey JA. Sibutramine: a serotoninnorepinephrine reuptake-inhibitor for the treatment of obesity. Arm Pharmacother 1999; 33(9): 968-978.
11. Golozoubova V, Strauss F, Malmlof K. Locomotion is the major determinant of sibutramine-induced increase in energy expenditure. Pharmacol Biochem Behav 2006; 83(4): 517-527.